PMID- 27329593
OWN - NLM
STAT- MEDLINE
DCOM- 20180109
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 28
DP  - 2016 Jul 12
TI  - Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review 
      and meta-analysis.
PG  - 44545-44557
LID - 10.18632/oncotarget.10019 [doi]
AB  - To systematically review the safety and efficacy of lenvatinib in the treatment 
      of patients, we retrieved all the relevant clinical trials on the adverse events 
      (AEs) and survival outcomes of lenvatinib through PubMed, Medline, Embase, Web of 
      Science and Cochrane Collaboration's Central register of controlled trial. 
      Fourteen eligible studies involving a total of 978 patients were included in our 
      analysis. The most common all-grade AEs observed in patients treated with 
      lenvatinib were hematuria (56.6%), fatigue (52.2%) and decreased appetite 
      (50.5%). The most frequently observed grade >/=3 AEs were thrombocytopenia (25.4%), 
      hypertension (17.7%) and edema peripheral (15.5%). The incidences of both 
      all-grade and high-grade hypertension were significantly increased. Meanwhile, 
      the controlled trial suggested that progression free survival (PFS) was 
      significantly longer in the lenvatinib group than the placebo group. Subgroup 
      analyses showed that mean PFS for renal cell carcinoma was 10.933+/-1.828 months 
      (95% CI 7.350-14.515, p < 0.001), and that for thyroid cancer was 18.344+/-0.083 
      months (95% CI 18.181-18.506, p < 0.001). In conclusion, lenvatinib is an 
      effective agent in thyroid cancer. Early monitoring and effective management of 
      side effects are crucial for the safe use of this drug.
FAU - Zhu, Chenjing
AU  - Zhu C
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 
      610041, PR China.
FAU - Ma, Xuelei
AU  - Ma X
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 
      610041, PR China.
FAU - Hu, Yuanyuan
AU  - Hu Y
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu 
      610041, PR China.
FAU - Guo, Linghong
AU  - Guo L
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu 
      610041, PR China.
FAU - Chen, Bo
AU  - Chen B
AD  - Department of Oncology, The First People's Hospital of Chengdu City, Chengdu 
      610041, PR China.
FAU - Shen, Kai
AU  - Shen K
AD  - State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, 
      Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 
      610041, PR China.
FAU - Xiao, Yue
AU  - Xiao Y
AD  - West China School of Medicine, West China Hospital, Sichuan University, Chengdu 
      610041, PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Antineoplastic Agents/adverse effects/therapeutic use
MH  - Disease-Free Survival
MH  - Fatigue/chemically induced
MH  - Hematuria/chemically induced
MH  - Humans
MH  - Hypertension/chemically induced
MH  - Neoplasms/*drug therapy
MH  - Phenylurea Compounds/adverse effects/*therapeutic use
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
PMC - PMC5190117
OTO - NOTNLM
OT  - cancer
OT  - efficacy
OT  - lenvatinib
OT  - meta-analysis
OT  - safety
COIS- All authors declare no conflicts of interest
EDAT- 2016/06/23 06:00
MHDA- 2018/01/10 06:00
PMCR- 2016/07/12
CRDT- 2016/06/23 06:00
PHST- 2016/01/30 00:00 [received]
PHST- 2016/05/17 00:00 [accepted]
PHST- 2016/06/23 06:00 [pubmed]
PHST- 2018/01/10 06:00 [medline]
PHST- 2016/06/23 06:00 [entrez]
PHST- 2016/07/12 00:00 [pmc-release]
AID - 10019 [pii]
AID - 10.18632/oncotarget.10019 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Jul 12;7(28):44545-44557. doi: 10.18632/oncotarget.10019.